Correction to: 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2018; Lippincott Williams & Wilkins; Volume: 71; Issue: 6 Linguagem: Inglês
10.1161/hyp.0000000000000076
ISSN1524-4563
Tópico(s)Cardiac, Anesthesia and Surgical Outcomes
ResumoHomeHypertensionVol. 71, No. 6Correction to: 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines Free AccessCorrectionPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessCorrectionPDF/EPUBCorrection to: 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines Originally published9 May 2018https://doi.org/10.1161/HYP.0000000000000076Hypertension. 2018;71:e140–e144This article corrects the following2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice GuidelinesIn the article by Whelton et al, “2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines,” which published ahead of print on November 13, 2017, and appeared in the June 2018 issue of the journal (Hypertension. 2018;71:e13–e115. DOI: 10.1161/HYP.0000000000000065), several corrections were needed.On page e13, in the author list, “FACC” has been removed after Dr. Giddings’ name.On page e14, in the Table of Contents and on page e57, the 9.5. heading read, “9.5. Peripheral Arterial Disease.” It has been updated to read, “9.5. Peripheral Artery Disease.” It has also been updated on page e76 in Table 22 and on page e77 in Table 23.On page e20, in the footnote for Table 5, second paragraph, last sentence, the reference 12 citation has been removed from the end of the sentence.On page e27, Figure 1, bottom row, needed the following changes:The third box from the left (“Masked Hypertension”) was labeled as Class IIb. It has been updated to Class IIa. The shading of the box has been updated also.The fourth box from the left (“Elevated BP”) was labeled as Class IIb. It has been updated to Class IIa. The shading of the box has been updated also.On page e28, Figure 2, bottom row, the second box from the left read, “Continue current therapy (Class IIa).” It has been updated to read, “Continue current therapy”; the Class of Recommendation color has been removed.On page e33, in Table 14, the text in the first column, last row read, “Angiogenesis inhibitor (eg, bevacizumab) and tyrosine kinase inhibitors (eg, sunitinib, sorafenif).” It has been updated to read, “Angiogenesis inhibitor (eg, bevacizumab) and tyrosine kinase inhibitors (eg, sunitinib, sorafenib).”On page e35, section “6.2. Nonpharmacological Interventions,” under “Synopsis,” first paragraph, the first sentence read, “Nonpharmacological interventions…sodium reduction (8–11), potassium supplementation (13,17), increased physical activity (18–20,22,31), and ….” It has been updated to read, “Nonpharmacological interventions…sodium reduction,S6.2-8–S6.2-12 potassium supplementation,S6.2-13,S6.2-17 increased physical activity,S6.2-18–S6.2-22,S6.2-31 and….”On page e35, section “6.2. Nonpharmacological Interventions,” under “Synopsis,” first paragraph, the third sentence read, “Such interventions include…low-carbohydrate and vegetarian diets (5,7,46–49), (18–20,22,23,31,50).” It has been updated to read, “Such interventions include…low-carbohydrate, vegetarian, and Mediterranean diet.S6.2-46–S6.2-49”On page e36, section “6.2. Nonpharmacological Interventions,” under “Synopsis,” the last paragraph, which read, “Table 15 is a summary of best proven nonpharmacological interventions for prevention and treatment of hypertension.” has been deleted.On page e37, section “6.2. Nonpharmacological Interventions,” under “Recommendation-Specific Supportive Text,” third paragraph, the third sentence read, “Lifestyle change… on the DASH diet (5) or following a weight loss intervention (12).” It has been updated to read, “Lifestyle change…on the DASH dietS6.2–5 or receiving a weight loss intervention.S6.2–12”On page e37, section “6.2. Nonpharmacological Interventions,” under “Recommendation-Specific Supportive Text,” fourth paragraph, the last sentence read, “This can be achieved by a diet…high in potassium content (6).” It has been updated to read, “This can be achieved by a diet…high in potassium content.S6.2–7”On page e40, section “8.1.2. BP Treatment Threshold and the Use of CVD Risk Estimation to Guide Drug Treatment of Hypertension,” under “Synopsis,” second paragraph, the third from the last sentence read, “It should be kept in mind…adults ages 45 to 79 years….” It has been updated to read, “It should be kept in mind…adults ages 40 to 79 years….”On page e41, legend to Figure 4, the third sentence, read, “*Using the ACC/AHA Pooled Cohort Equations (57).” It has been updated to read, “*Using the ACC/AHA Pooled Cohort Equations.S8.1.2–56,S8.1.2–57”On page e42, the section “8.1.3. Follow-Up After Initial BP Evaluation” recommendation table title read, “Recommendations for Follow-Up After Initial BP Elevation.” It has been updated to read, “Recommendations for Follow-Up After Initial BP Evaluation.”On pages e44 and e45, in “Table 18. Oral Antihypertensive Drugs,” the following updates have been made:In the “Primary agents” section, the first row “Thiazide or thiazide-type diuretics,” the “Metolazone” section, the “Usual Dose, Range (mg/d)*”column read, “2.5–10.” It has been updated to read, “2.5–5.”In the “Primary agents” section, the second row “ACE inhibitors,” the “Ramipril” section, the “Usual Dose, Range (mg/d)*”column read, “2.5–10.” It has been updated to read, “2.5–20.”In the “Primary agents” section, the fourth row “CCB—dihydropyridines,” the “Felodipine” section, the “Usual Dose, Range (mg/d)*”column read, “5–10.” It has been updated to read, “2.5–10.”In the “Primary agents” section, the fourth row “CCB—dihydropyridines,” the “Nicardipine SR” section, the “Usual Dose, Range (mg/d)*”column read, “5–20.” It has been updated to read, “60–120.” The “Daily Frequency” column read, “1.” It has been updated to read, “2.”In the “Primary agents” section, the fourth row “CCB—dihydropyridines,” the “Nifedipine LA” section, the “Usual Dose, Range (mg/d)*”column read, “60–120.” It has been updated to read, “30–90.”In the “Primary agents” section, the fourth row “CCB—dihydropyridines,” the “Nisoldipine” section, the “Usual Dose, Range (mg/d)*”column read, “30–90.” It has been updated to read, “17–34.”In the “Primary agents” section, the fifth row “CCB—nondihydropyridines,” the “Diltiazem SR” section has been removed.In the “Primary agents” section, the fifth row “CCB—nondihydropyridines,” the “Diltiazem ER” section, the “Usual Dose, Range (mg/d)*”column read, “120–480.” It has been updated to read, “120–360.”In the “Primary agents” section, the fifth row “CCB—nondihydropyridines,” the “Verapamil IR” section, the “Usual Dose, Range (mg/d)*”column read, “40–80.” It has been updated to read, “120–360.”In the “Primary agents” section, the fifth row “CCB—nondihydropyridines,” the “Verapamil SR” section, the “Usual Dose, Range (mg/d)*”column read, “120–480.” It has been updated to read, “120–360.”In the “Primary agents” section, the fifth row “CCB—nondihydropyridines,” the “Verapamil-delayed onset ER” section, the “Drug” column read, “Verapamil-delayed onset ER (various forms).” It has been updated to read, “Verapamil-delayed onset ER.”In the “Primary agents” section, the fifth row “CCB—nondihydropyridines,” the “Verapamil-delayed onset ER” section, the “Usual Dose, Range (mg/d)*”column read, “100–480.” It has been updated to read, “100–300.”In the “Secondary agents” section, the first row “Diuretics—loop,” the “Bumetanide” section, the “Usual Dose, Range (mg/d)*”column read, “0.5–4.” It has been updated to read, “0.5–2.”In the “Secondary agents” section, the third row “Diuretics—aldosterone antagonists,” the “Eplerenone” section, the “Daily Frequency” column read, “12.” It has been updated to read, “1 or 2.”In the “Secondary agents” section, the fourth row “Beta blockers—cardioselective,” the “Atenolol” section, the “Daily Frequency” column read, “12.” It has been updated to read, “2.”In the “Secondary agents” section, the fourth row “Beta blockers—cardioselective,” the “Metoprolol tartrate” section, the “Usual Dose, Range (mg/d)*”column read, “100–400.” It has been updated to read, “100–200.”In the “Secondary agents” section, the fourth row “Beta blockers—noncardioselective,” the “Propranolol IR” section, the “Usual Dose, Range (mg/d)*”column read, “160–480.” It has been updated to read, “80–160.”In the “Secondary agents” section, the sixth row “Beta blockers—noncardioselective,” the “Propranolol LA” section, the “Usual Dose, Range (mg/d)*”column read, “80–320.” It has been updated to read, “80–160.”In the “Secondary agents” section, the seventh row “Beta blockers—intrinsic sympathomimetic activity,” the “Carteolol” section has been deleted.In the “Secondary agents” section, the tenth row “Alpha-1 blockers,” the “Doxazosin” section, the “Usual Dose, Range (mg/d)*”column read, “1–8.” It has been updated to read, “1–16.”In the “Secondary agents” section, the penultimate row, the “Class” column read, “Central alpha1-agonist and other centrally acting drugs.” It has been updated to read, “Central alpha2-agonist and other centrally acting drugs.”In the “Secondary agents” section, the last row “Direct vasodilators,” the “Hydralazine” section, the “Usual Dose, Range (mg/d)*”column read, “250–200.” It has been updated to read, “100–200.”On page e46, in section “8.1.6. Choice of Initial Medication” under “Synopsis,” first paragraph, the second sentence read, “When initiation of pharmacological… are indicated (see Section 9) (1,3).” It has been updated to read, “When initiation of pharmacological… are indicated (see Section 9).S8.1.6-1”On page e46, in section “8.1.6. Choice of Initial Medication” under “Synopsis,” first paragraph, the third sentence read, “In the largest head-to-head comparison of first-step drug therapy for hypertension (4,5), the….” It has been updated to read, “In the largest head-to-head comparison of first-step drug therapy for hypertension,S8.1.6–3 the….”On page e46, in section “8.1.6. Choice of Initial Medication” under “Synopsis,” first paragraph, the fifth sentence read, “For black patients, ACE inhibitors were also notably less effective than CCBs in preventing HF (5,10) and in the prevention of stroke (11,12)….” It has been updated to read, “For black patients, ACE inhibitors were also notably less effective than CCBs in preventing HFS8.1.6–8 and in the prevention of strokeS8.1.6–9….”On page e57, Figure 9, fourth row, the first box on the left read, “Aim for BP <140/90 mm Hg (Class IIb).” It has been updated to read, “Aim for BP <130/80 mm Hg (Class IIb).”On page e64, in section “10.3.2. Children and Adolescents,” the last sentence read, “Publication of new evidence-based pediatric guidelines is anticipated in late 2017.” It has been updated to read, “A new pediatric BP guideline was published in late 2017.S10.3.2-7”On page e69, in section “11.4. Sexual Dysfunction and Hypertension,” the second sentence read, “Although these data converge to suggest that endothelial dysfunction is a common denominator, the story is complete.” It has been updated to read, “Although these data converge to suggest that endothelial dysfunction is a common denominator, the story is incomplete.”On page e70, in section “11.5. Patients Undergoing Surgical Procedures,” under “Recommendation-Specific Supportive Text,” the second paragraph, the third sentence read, “Special consideration of placement on parenteral therapy usually occurs for patients….” It has been updated to read, “Special consideration of parenteral therapy usually occurs for patients….”On page e77, Table 23, in the “Specific comorbidities” section, the penultimate row “Secondary stroke prevention (lacunar)” has been deleted.On page e78, in the “Presidents and Staff” section for the American Heart Association, Ms. Hundley’s title has been updated to read, “Manager, Production and Operations.”On page e92, in the References for section “8.1.2. BP Treatment Threshold and the Use of CVD Risk Estimation to Guide Drug Treatment of Hypertension,” the following changes were made:A reference was added: “S8.1.2-56. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(suppl 2):S49–73.Reference “14. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(suppl 2):S1-45” has been renumbered as “S8.1.2-57.”On page e93, in the References for section “8.1.5. BP Goal for Patients With Hypertension,” reference 16 (now reference S8.1.5-16) read, “Taler SJ, Textor SC, Canzanello VJ, et al. Role of steroid dose in hypertension early after liver transplantation with tacrolimus (FK506) and cyclosporine. Transplantation. 1996;62:1588–92.” It has been updated to read, “SPS3 Study Group. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet. 2013;382:507–15.”On page e93, in the references for section “8.1.6. Choice of Initial Medication,” 3 references were deleted:Peart S. Results of MRC (UK) trial of drug therapy for mild hypertension. Clin Invest Med. 1987;10:616–20.Julius S, Weber MA, Kjeldsen SE, et al. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. Hypertension. 2006;48:385–91.Zanchetti A, Julius S, Kjeldsen S, et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial. J Hypertens. 2006;24:2163–8.On page e103, in the References for section “10.3.2. Children and Adolescents,” a new reference was added to the section: “S10.3.2-7. Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics. 2017;140:e20171904.”On page e108, in Appendix 1, for Dr. Carey, column 2 “Employment” read, “University of Virginia—Dean Emeritus and University Professor, Department of Medicine.” It has been updated to read, “University of Virginia School of Medicine—Dean, Emeritus, and Professor of Medicine.” Column 6 “Personal Research” read, “None.” It has been updated to read, “Daiichi Sankyo Inc†”On page e108, in Appendix 1, for Dr. Ovbiagele, column 4, “Speakers Bureau,” read, “None.” It has been updated to read, “Boehringer Ingelheim Korea Ltd.”On page e109, in Appendix 1, for Dr. Wright, column 4, “Speakers Bureau,” read, “None.” It has been updated to read, “Amgen†.”On page e109, in the Appendix 1 footnotes, the first paragraph has been deleted. It read:This table represents the relationships of committee members with industry and other entities (RWI) that are considered relevant to this document. Although most ACC/AHA guideline writing committees are constituted such that no more than half the members may have relevant RWI for 1 year before and during development of the guideline, rules for the prevention guidelines require that no members have relevant RWI from 1 year before appointment until 1 year after publication of the guideline. Members’ RWI were reviewed and updated at all meetings and conference calls of the writing committee during the document development period. The complete ACC/AHA policy on RWI is available at http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy.It has been updated with 2 new paragraphs to read:This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$5000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted.According to the ACC/AHA, a person has a relevant relationship IF: a) the relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; or b) the company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document, or makes a competing drug or device addressed in the document; or c) the person or a member of the person’s household, has a reasonable potential for financial, professional or other personal gain or loss as a result of the issues/content addressed in the document.On page e109, in the Appendix 1 footnotes, “†Significant relationship.” has been added.In the Comprehensive RWI Data Supplement for the writing committee, the following updates have been made:For Dr. Carey, column 2 “Employment” read, “University of Virginia—Dean Emeritus and University Professor, Department of Medicine.” It has been updated to read, “University of Virginia School of Medicine—Dean, Emeritus, and Professor of Medicine.” Column 6, “Personal Research” read, “None.” It has been updated to read, “Daiichi Sankyo Inc*.”For Dr. Ovbiagele, column 4, “Speakers Bureau” read, “None.” It has been updated to read, “Boehringer Ingelheim Korea Ltd.”For Dr. Wright, column 4, “Speakers Bureau” read, “None.” It has been updated to read, “Amgen*.”These corrections have been made to the current online version of the article, which is available at http://hyper.ahajournals.org/lookup/doi/10.1161/HYP.0000000000000065. Previous Back to top Next FiguresReferencesRelatedDetailsCited By Tang J, Zhu Q, Xu Y, Zhou Y, Zhu L, Jin L, Wang W, Gao L, Chen G and Zhao H (2022) Total arsenic, dimethylarsinic acid, lead, cadmium, total mercury, methylmercury and hypertension among Asian populations in the United States: NHANES 2011–2018, Ecotoxicology and Environmental Safety, 10.1016/j.ecoenv.2022.113776, 241, (113776), Online publication date: 1-Aug-2022. Abbott A (2022) Extra-Cranial Carotid Artery Stenosis: An Objective Analysis of the Available Evidence, Frontiers in Neurology, 10.3389/fneur.2022.739999, 13 Kapur G, Stenson A, Chiodo L, Delaney-Black V, Hannigan J, Janisse J and Ratner H (2022) Childhood Violence Exposure Predicts High Blood Pressure in Black American Young Adults, The Journal of Pediatrics, 10.1016/j.jpeds.2022.05.039, Online publication date: 1-Jun-2022. Shalimova A (2022) INSUFFICIENT CONTROL OF OUT-OF-OFFICE BLOOD PRESSURE: THE PROBLEM OF MASKED UNCONTROLLED HYPERTENSION: review, Inter Collegas, 10.35339/ic.8.4.201-210, 8:4, (201-210) Vitto C, Lykins V J, Wiles-Lafayette H and Aurora T (2022) Blood Pressure Assessment and Treatment in the Observation Unit, Current Hypertension Reports, 10.1007/s11906-022-01196-3 Li S, Liu H, Guo Y, Zhu C, Wu N, Xu R, Dong Q, Qian J, Dou K and Li J (2022) Current Guideline Risk Stratification and Cardiovascular Outcomes in Chinese Patients Suffered From Atherosclerotic Cardiovascular Disease, Frontiers in Endocrinology, 10.3389/fendo.2022.860698, 13 Huang X, Liu J, Zhang L, Wang B, Bai X, Hu S, Miao F, Tian A, Yang T, Li Y and Li J (2022) Systolic Blood Pressure and 1-Year Clinical Outcomes in Patients Hospitalized for Heart Failure, Frontiers in Cardiovascular Medicine, 10.3389/fcvm.2022.877293, 9 Stavropoulos K, Imprialos K, Patoulias D, Katsimardou A and Doumas M (2022) Impact of Primary Aldosteronism in Resistant Hypertension, Current Hypertension Reports, 10.1007/s11906-022-01190-9 Hermida-Ayala R, Mojón A, Fernández J, Smolensky M and Hermida R (2021) Ingestion-time differences in the pharmacodynamics of dual-combination hypertension therapies: Systematic review and meta-analysis of published human trials, Chronobiology International, 10.1080/07420528.2021.2005084, 39:4, (493-512), Online publication date: 3-Apr-2022. Psarova V, Kochuieva M, Gogunska I, Shchur O, Kochuiev G and Tymchenko H (2022) THE RELATIONSHIPS OF IRS-1 POLYMORPHISM WITH HEMODYNAMIC DISORDERS IN HYPERTENSIVE PATIENTS DEPENDING ON BODY WEIGHT AND METABOLIC COMORBIDITY, Wiadomości Lekarskie, 10.36740/WLek20220420107, 75:4, (959-964), Online publication date: 1-Apr-2022. Kong G, Chew N, Ng C, Chin Y, Lim O, Ambhore A, Ng G, Kong W, Poh K, Foo R, Yip J, Yeo T, Low A, Lee C, Chan M, Tan H and Loh P (2022) Prognostic Outcomes in Acute Myocardial Infarction Patients Without Standard Modifiable Risk Factors: A Multiethnic Study of 8,680 Asian Patients, Frontiers in Cardiovascular Medicine, 10.3389/fcvm.2022.869168, 9 Nakamura M, Yaku H, Ako J, Arai H, Asai T, Chikamori T, Daida H, Doi K, Fukui T, Ito T, Kadota K, Kobayashi J, Komiya T, Kozuma K, Nakagawa Y, Nakao K, Niinami H, Ohno T, Ozaki Y, Sata M, Takanashi S, Takemura H, Ueno T, Yasuda S, Yokoyama H, Fujita T, Kasai T, Kohsaka S, Kubo T, Manabe S, Matsumoto N, Miyagawa S, Mizuno T, Motomura N, Numata S, Nakajima H, Oda H, Otake H, Otsuka F, Sasaki K, Shimada K, Shimokawa T, Shinke T, Suzuki T, Takahashi M, Tanaka N, Tsuneyoshi H, Tojo T, Une D, Wakasa S, Yamaguchi K, Akasaka T, Hirayama A, Kimura K, Kimura T, Matsui Y, Miyazaki S, Okamura Y, Ono M, Shiomi H and Tanemoto K (2022) JCS/JSCVS 2018 Guideline on Revascularization of Stable Coronary Artery Disease, Circulation Journal, 10.1253/circj.CJ-20-1282, 86:3, (477-588), Online publication date: 25-Feb-2022. Sun Q, Pan Y, Zhao Y, Liu Y and Jiang Y (2022) Association of Nighttime Systolic Blood Pressure With Left Atrial-Left Ventricular–Arterial Coupling in Hypertension, Frontiers in Cardiovascular Medicine, 10.3389/fcvm.2022.814756, 9 González-Rivas J, Infante-García M, Nieto-Martinez R, Mechanick J and Danaei G (2022) Feasibility and Effectiveness of a Preventive Care Program during the Compound Humanitarian Crisis and COVID-19 Pandemic in Venezuela, Nutrients, 10.3390/nu14050939, 14:5, (939) Sen A and Baruah G (2022) RELATIONSHIP OF ELECTROCARDIOGRAM VARIABLES WITH BLOOD PRESSURE IN UNDERGRADUATE MEDICAL STUDENTS., GLOBAL JOURNAL FOR RESEARCH ANALYSIS, 10.36106/gjra/9609721, (76-78), Online publication date: 15-Feb-2022. Gilbert-Ouimet M, Trudel X, Talbot D, Vézina M, Milot A and Brisson C (2021) Long working hours associated with elevated ambulatory blood pressure among female and male white-collar workers over a 2.5-year follow-up, Journal of Human Hypertension, 10.1038/s41371-021-00499-3, 36:2, (207-217), Online publication date: 1-Feb-2022. Lu Z, Song Y, Chen H, Li S, Teo E and Gu Y (2022) A Mixed Comparisons of Aerobic Training With Different Volumes and Intensities of Physical Exercise in Patients With Hypertension: A Systematic Review and Network Meta-Analysis, Frontiers in Cardiovascular Medicine, 10.3389/fcvm.2021.770975, 8 Chen H, Gong J, Xing K, Liu M, Ren H and Luo J (2022) Pharmacomicrobiomics: Exploiting the Drug-Microbiota Interactions in Antihypertensive Treatment, Frontiers in Medicine, 10.3389/fmed.2021.742394, 8 Gumprecht J and Kalarus Z (2022) ATRIAL FIBRILLATION IN PATIENTS WITH CONCOMITANT DIABETES MELLITUS – WHAT DO WE ALREADY KNOW AND WHAT DO WE NEED TO DISCOVER?, Wiadomości Lekarskie, 10.36740/WLek202201123, 75:1, (123-127), Online publication date: 1-Jan-2022. Alcocer L (2022) Gestión de la hipertensión arterial en adultos mayores: envejecimiento, senescencia y edadismo, Cardiovascular and Metabolic Science, 10.35366/105191, 33:S3, (244-249), . Múnera-Echeverri A and Ruiz-Gastelum E (2022) Tratamiento de la hipertensión arterial durante todos los trimestres del embarazo, Cardiovascular and Metabolic Science, 10.35366/105190, 33:S3, (238-243), . Pavía-López A, Pazos-Pérez F and Chávez-Mendoza A (2022) Una revisión de las terapias no farmacológicas y farmacológicas para tratar la hipertensión arterial, Cardiovascular and Metabolic Science, 10.35366/105188, 33:S3, (223-232), . Pavía López A, Pavía Aubry V, López Jalil H, Conde Carmona I and Ángel Juárez V (2022) Relación entre el sistema renina angiotensina aldosterona y las complicaciones cardiovasculares por SARS-CoV-2, Anales Médicos de la Asociación Médica del Centro Médico ABC, 10.35366/104366, 67:1, (34-43), . Lee M, George J, Shahab H, Hermel M, Rana J and Virani S (2022) Highlights of Cardiovascular Disease Studies Presented at the 2021 American Heart Association Scientific Sessions, Current Atherosclerosis Reports, 10.1007/s11883-022-00985-0, 24:1, (61-72), Online publication date: 1-Jan-2022. Yahr J, Calle J and Taliercio J (2021) A renaissance in the treatment of diabetic kidney disease, hypertension in chronic kidney disease, and beyond, Journal of Osteopathic Medicine, 10.1515/jom-2021-0150, 122:1, (55-63), Online publication date: 21-Dec-2021., Online publication date: 1-Jan-2022. Dotsenko N, Herasymenko L, Shekhunova I, Boev S, Molodan А, Malinovskaya A and Yatsenko O (2021) Variability of arterial hypertension as an additional factor to cardiovascular risk in atrial fibrillation, Modern medical technology, 10.34287/MMT.4(51).2021.8:4(51), (41-46) Jordão M, Ceroni A and Michelini L (2021) Perfusion of Brain Preautonomic Areas in Hypertension: Compensatory Absence of Capillary Rarefaction and Protective Effects of Exercise Training, Frontiers in Physiology, 10.3389/fphys.2021.773415, 12 Agaltsov M and Korostovtseva L (2021) Obstructive sleep apnea and cardiovascular comorbidity: modern discordance in assessing the effectiveness of CPAP-therapy against the pathogenetic mechanisms and cardiovascular diseases, PULMONOLOGIYA, 10.18093/0869-0189-2021-31-6-799-807, 31:6, (799-807) Kang S, Lee D, Han K, Jung J, Park S, Dai A, Wei H, Yoon C, Youn T, Chae I and Kim C (2021) Hypertension, renin-angiotensin-aldosterone-system-blocking agents, and COVID-19, Clinical Hypertension, 10.1186/s40885-021-00168-0, 27:1, Online publication date: 1-Dec-2021. Shokr H and Gherghel D (2021) European Society of Cardiology/European Society of Hypertension versus the American College of Cardiology/American Heart Association guidelines on the cut-off values for early hypertension: a microvascular perspective, Scientific Reports, 10.1038/s41598-021-83096-1, 11:1, Online publication date: 1-Dec-2021. Romero C, Tabares A and Orias M (2021) Is Isolated Diastolic Hypertension an Important Phenotype?, Current Cardiology Reports, 10.1007/s11886-021-01609-w, 23:12, Online publication date: 1-Dec-2021. Liu J, Su X, Nie Y, Zeng Z and Chen H (2021) Dosing Time Matters? Nighttime vs. Daytime Administration of Nifedipine Gastrointestinal Therapeutic System (GITS) or Amlodipine on Non-dipper Hypertension: A Randomized Controlled Trial of NARRAS, Frontiers in Cardiovascular Medicine, 10.3389/fcvm.2021.755403, 8 DeJongh B (2021) Clinical pearls for the monitoring and treatment of antipsychotic induced metabolic syndrome, Mental Health Clinician, 10.9740/mhc.2021.11.311, 11:6, (311-319), Online publication date: 1-Nov-2021. Ranadive S, Dillon G, Mascone S and Alexander L (2021) Vascular Health Triad in Humans With Hypertension—Not the Usual Suspects, Frontiers in Physiology, 10.3389/fphys.2021.746278, 12 Russell N and Grossmann M (2021) Management of bone and metabolic effects of androgen deprivation therapy, Urologic Oncology: Seminars and Original Investigations, 10.1016/j.urolonc.2018.10.007, 39:10, (704-712), Online publication date: 1-Oct-2021. McMahon M, Seto R and Skaggs B (2021) Cardiovascular disease in systemic lupus erythematosus, Rheumatology and Immunology Research, 10.2478/rir-2021-0022, 2:3, (157-172), Online publication date: 1-Sep-2021., Online publication date: 1-Sep-2021. Jacobs Z (2021) Hypertensive “Urgency” Is a Harmful Misnomer, Journal of General Internal Medicine, 10.1007/s11606-020-06495-6, 36:9, (2812-2813), Online publication date: 1-Sep-2021. Katamanova E, Efimova N, Kazakova P, Ushakova O and Kodinets I Risk factors, quality of life and health of the elderly age persons, Hygiene and sanitation, 10.47470/0016-9900-2021-100-8-863-868, 100:8, (863-868) Kumar R, Kant S, Chandra A and Krishnan A (2021) Tobacco use and nicotine dependence among patients with diabetes and hypertension in Ballabgarh, India, Monaldi Archives for Chest Disease, 10.4081/monaldi.2021.1799 Nelly N and Hamamouchi I (2021) Treat to Target in Spondyloarthritis: Myth or Reality?, EMJ Rheumatology, 10.33590/emjrheumatol/21-00071, (115-128) Hackler E, Hamburg N and White Solaru K (2021) Racial and Ethnic Disparities in Peripheral Artery Disease, Circulation Research, 128:12, (1913-1926), Online publication date: 11-Jun-2021. Farahani S, Farahani I, Burckhardt B, Monser K and Laeer S (2021) The Development of an Educational Video on Blood Pressure Measurement for Pharmacy Students, Advances in Medical Education and Practice, 10.2147/AMEP.S302728, Volume 12, (655-663) Michels M, Spivakoski C, Réus B, Alves D, Mattje P, Hohl A, Ronsoni M and Sande‐Lee S (2021) Effect of whole body vibration on clinical and metabolic outcomes in adults with type 2 diabetes: an observational pilot trial, Practical Diabetes, 10.1002/pdi.2337, 38:3, (20-25), Online publication date: 1-May-2021. Gubareva E, Fatenkov O, Gubareva I, Klimenko D, Shvan L and Limareva L (2021) Orthostatic hypertension in cardiovascular risk stratification in hypertensive patients, Russian Journal of Cardiology, 10.15829/560-4071-2021-4221, 26, (4221) Shao T, Li X, Zhou C, Zang X, Malone D, Zhang L, Zhou J and Tang W (2021) Effectiveness and Efficiency of Non-drug Therapy Among Community-Dwelling Adults With Hypertension in China: A Protocol for Network Meta-Analysis and Cost-Effectiveness Analysis, Frontiers in Medicine, 10.3389/fmed.2021.651559, 8 Qiao W, Zhang X, Kan B, Vuong A, Xue S, Zhang Y, Li B, Zhao Q, Guo D, Shen X and Yang S (2021) Hypertension, BMI, and cardiovascular and cerebrovascular diseases, Open Medicine, 10.1515/med-2021-0014, 16:1, (149-155), Online publication date: 21-Jan-2021., Online publication date: 1-Jan-2021. Dharmarajan K (2021) Water, Potassium, Sodium, and Chloride in Nutrition Geriatric Gastroenterology, 10.1007/978-3-319-90761-1_94-1, (1-16), . Dharmarajan K (2021) Water, Potassium, Sodium, and Chloride in Nutrition Geriatric Gastroenterology, 10.1007/978-3-030-30192-7_94, (539-554), . Steinberg D, Kay M, Svetkey L, Askew S, Christy J, Burroughs J, Ahmed H and Bennett G (2020) Feasibility of a Digital Health Intervention to Improve Diet Quality Among Women With High Blood Pressure: Randomized Controlled Feasibility Trial, JMIR mHealth and uHealth, 10.2196/17536, 8:12, (e17536) Ramezankhani A, Blaha M, Mirbolouk M, Azizi F and Hadaegh F (2020) Multi-state analysis of hypertension and mortality: application of semi-Markov model in a longitudinal cohort study, BMC Cardiovascular Disorders, 10.1186/s12872-020-01599-7, 20:1, Online publication date: 1-Dec-2020. Meng X and Xu X (2020) What Is the Ideal Blood Pressure Treatment Target for Primary Prevention and Management of Atrial Fibrillation?, Frontiers in Cardiovascular Medicine, 10.3389/fcvm.2020.586183, 7 Lozada Zapata A, Piscoya J, Shiraishi Zapata C and Mendieta Albañil W (2020) Calidad de vida y adherencia terapéutica en un programa de hipertensión arterial, Revista de Salud Pública, 10.15446/rsap.v22n6.88007, 22:6, (1-8) Newman J, Rajagopalan S, Levy P and Brook R (2020) Clearing the air to treat hypertension, Journal of Human Hypertension, 10.1038/s41371-020-0358-9, 34:11, (759-763), Online publication date: 1-Nov-2020. Okada H (2020) 2. Strategic Application of Clinical Practice Guideline for CKD Management2．CKD対策における診療ガイドラインの戦略的意義, Nihon Naika Gakkai Zasshi, 10.2169/naika.109.1698, 109:9, (1698-1707), Online publication date: 10-Sep-2020. Zamora Z and Williamson J (2020) The Effects of Lower BP Goals on Cognitive Function in the Elderly, Current Cardiology Reports, 10.1007/s11886-020-01312-2, 22:8, Online publication date: 1-Aug-2020. Kuramoto M, Aizawa M, Kuramoto Y, Okabe M, Sakata Y and Aizawa Y (2020) Blood Pressure Increases Before Pulse Rate During the Nocturnal Period in Hypertensive Patients, International Heart Journal, 10.1536/ihj.19-695, 61:3, (579-584), Online publication date: 30-May-2020. Watanabe T, Satoh H, Sugawara Y, Tsukita J, Goto T and Kikuchi A (2020) The Current State of Blood Pressure Measurement in Medical Examination Institutions—A Study Based on Questionnaire Replies—健診における血圧測定法の現状, Health Evaluation and Promotion, 10.7143/jhep.47.463, 47:3, (463-468), Online publication date: 10-May-2020. Babic M (2020) Die maskierte Hypertonie - eine diagnostische Herausforderung, CardioVasc, 10.1007/s15027-019-0012-z, 20:1, (31-33), Online publication date: 1-Feb-2020. Vergara Suárez A, Flores Fajardo Q, Saucedo Moreno and Ezquerra Osorio A (2020) Evaluación de la técnica en la toma de presión arterial en un Hospital de Tercer Nivel en México, Acta Médica Grupo Ángeles, 10.35366/97261, 18:4, (360-366), . Karetnikova V, Zvereva T and Barbarash O (2019) Current features of management of comorbid patients with hypertension, Medical alphabet, 10.33667/2078-5631-2019-2-30(405)-6-11, 2:30, (6-11) Sprigg N, Flaherty K, Appleton J, Al-Shahi Salman R, Bereczki D, Beridze M, Ciccone A, Collins R, Dineen R, Duley L, Egea-Guerrero J, England T, Karlinski M, Krishnan K, Laska A, Law Z, Ovesen C, Ozturk S, Pocock S, Roberts I, Robinson T, Roffe C, Peters N, Scutt P, Thanabalan J, Werring D, Whynes D, Woodhouse L and Bath P (2019) Tranexamic acid to improve functional status in adults with spontaneous intracerebral haemorrhage: the TICH-2 RCT, Health Technology Assessment, 10.3310/hta23350, 23:35, (1-48) Babayeva N (2019) CLINICAL AND INSTRUMENTAL ASSESSMENT OF MORPHO-FUNCTIONAL CONDITION OF THE HEART AND VASCULATURE IN COMORBIDITY OF ARTERIAL HYPERTENSION AND DIABETES MELLITUS TYPE 2, Eurasian heart journal, 10.38109/2225-1685-2019-2-64-75:2, (64-75) Gray J and O’Malley P (2019) Review: E-health interventions improve blood pressure level and control in hypertension, Annals of Internal Medicine, 10.7326/ACPJ201906180-068, 170:12, (JC68), Online publication date: 18-Jun-2019. Priya T and Murugan u (2019) PREVALENCE OF HYPERTENSIVE RETINOPATHY IN NEWLY DIAGNOSED HYPERTENSIVE PATIENTS, Journal of Evidence Based Medicine and Healthcare, 10.18410/jebmh/2019/238, 6:14, (1141-1144), Online publication date: 5-Apr-2019. DEMIR A and DINCER M (2019) The relation between body mass index and end organ damage in white coat hypertension, Marmara Medical Journal, 10.5472/marumj.518986, (50-54) Vega L (2019) New blood pressure levels in Peruvian high altitude populations and the new North American high blood pressure guidelines, Journal of Cardiology & Current Research, 10.15406/jccr.2019.12.00446, 12:4, (84-87) Donato A (2018) In persistent hypertension, low-dose triple-pill therapy increased the likelihood of achieving target BP at 6 mo, Annals of Internal Medicine, 10.7326/ACPJC-2018-169-10-056, 169:10, (JC56), Online publication date: 20-Nov-2018. Lopes M and Pugliesi A (2018) Hipertensão arterial sistêmica: atualização no diagnóstico e tratamento, Revista Paulista de Reumatologia, 10.46833/reumatologiasp.2018.17.3.15-18:2018 jul-set;17(3), (15-18) Makó K, Ureche C and Jeremiás Z (2018) An Updated Review of Hypertensive Emergencies and Urgencies, Journal Of Cardiovascular Emergencies, 10.2478/jce-2018-0013, 4:2, (73-83), Online publication date: 1-Jun-2018., Online publication date: 1-Jun-2018. Lackland D, Beilin L, Campbell N, Jaffe M, Orias M, Ram C, Weber M and Zhang X (2018) Global Implications of Blood Pressure Thresholds and Targets, Hypertension, 71:6, (985-987), Online publication date: 1-Jun-2018.Related articles2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice GuidelinesPaul K. Whelton, et al. Hypertension. 2018;71:e13-e115 June 2018Vol 71, Issue 6 Advertisement Article InformationMetrics © 2018 American Heart Association, Inc.https://doi.org/10.1161/HYP.0000000000000076PMID: 29743247 Originally publishedMay 9, 2018 PDF download Advertisement
Referência(s)